DelveInsight: One Year Anniversary!

  • Home Blog Delveinsight celebrating one year anniversary

DelveInsight: One Year Anniversary!

Feb 27, 2015

Inline image 1

Thanks to our great Clients, Partners, Colleagues, Family and Friends, we’re celebrating the completion of our first year in business.

Thanks for helping to make DelveInsight a success!!

Downloads

Article in PDF

Recent Articles
  1. Beam’s BEAM-302 Earns FDA Orphan Drug Tag for AATD; Incannex’s IHL-42X Moves to Phase III After F...
  2. Business cocktail
  3. Moderna’s mRESVIA(R) FDA Approval; Novartis Scemblix® Phase III Data; Kite’s Tecartus for R...
  4. Fatty Acid Amide Hydrolase (FAAH) Inhibitor – an enzyme with novel therapeutic potential
  5. Symdeko’s approval; Erytech target solid tumors; Oncologie snapped bavituximab; Merck delivers
pharma-news-for-amylyx-cellectar-merck
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Amylyx’s AMX0114 Fast Tracked by FDA for ALS; Cellectar’s Iopofosine I 131 Granted FDA Breakthrough in Waldenstrom Macroglobulinemia; YolTech’s YOLT-101 Clears FDA IND for Familial Hypercholesterolemia; Oncovita’s MVdeltaC Gets FDA Orphan Tag for Pleural Mesothelioma; Merck’s ENFLONSIA Approved for RSV Prevention in Infants

Types of Mitochondrial Disorders and the Science Behind Them: A Journey from Dysfunction to Discovery
Articles

Types of Mitochondrial Diseases and the Science Behind Them: A Journey from Dysfunction to Discovery

pharma-news-for-beam-incannex-kura
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Beam’s BEAM-302 Earns FDA Orphan Drug Tag for AATD; Incannex’s IHL-42X Moves to Phase III After FDA Protocol OK; Kura and Kyowa Kirin’s Ziftomenib Gets FDA Priority Review in NPM1-Mutant AML; GSK’s Linerixibat NDA Accepted by FDA for PBC-Linked Pruritus; Ascendis’ TransCon CNP Granted FDA Priority Review for Achondroplasia

business consulting
DelveInsight
Market Research
loader
loader